
FDA Tells Broth Maker Gourmend It Will Not Act Against Its Low-FODMAP Labels, Likening Them to Gluten-Free Claims
In a Nov. 16 letter, the FDA told Gourmend Foods it does not consider the company's low-FODMAP label statements to be nutrient content claims and does not intend to take enforcement action against them, after an appeals court revived the company's First Amendment lawsuit.
The U.S. Food and Drug Administration (FDA) told Gourmend Foods, a maker of low-FODMAP broths and seasoning kits, that it does not intend to take enforcement action against the company’s low-FODMAP label statements. The Nov. 16, 2026, letter follows a federal appeals court ruling that revived a First Amendment lawsuit against the FDA and the U.S. Department of Agriculture (USDA), Food Dive reported.
TLDR
- FDA said it generally does not consider statements about FODMAP levels to be nutrient content claims.
- The agency compared them to gluten-free and modified lactose claims, which it treats as avoidance claims or statements of special dietary usefulness.
- FDA called part of a 2017 warning letter that treated a “low lactose content” claim as a nutrient content claim an error.
- The lawsuit also challenges a USDA policy, which the plaintiffs’ lawyers say has not changed.
What the Letter Says
The letter is signed by Claudine Kavanaugh, director of the Office of Nutrition and Food Labeling in FDA’s Human Foods Program. It says FDA evaluated the FODMAP statements on Gourmend’s FDA-regulated products. FDA said it does not consider them nutrient content claims and does not intend to take enforcement action on them as nutrient content claims, avoidance claims or statements of special dietary usefulness.
The letter adds limits. FDA reviews labels case by case and in the context of the whole label. Every label statement must still be truthful, not misleading and compliant with other rules.
FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides and polyols. People on low-FODMAP diets, often to manage irritable bowel syndrome (IBS), typically limit foods such as onions, garlic and dairy. Up to 45 million people in the U.S. have IBS, according to the International Foundation for Gastrointestinal Disorders, Food Dive reported.
How the Case Got Here
Gourmend, represented by the Institute for Justice, challenged the restrictions in 2023 along with a consumer, Michelle Przybocki. According to Food Dive, the company had applied to USDA to use the label on a beef broth, and USDA denied it after consulting FDA. A district court dismissed the case in 2024. On Aug. 3, 2026, the U.S. Court of Appeals for the Ninth Circuit revived it in part.
The Institute for Justice said FDA changed its position after the plaintiffs asked for a preliminary injunction. It said the USDA policy has not changed and that the case returns to the district court. Those points come from the plaintiffs’ lawyers. USDA’s position was not available in the sources reviewed.
Why It Matters
Food Dive noted that glucagon-like peptide-1 (GLP-1) drugs, which slow digestion, could widen interest in low-FODMAP labels. The letter is addressed to one company, and Food Dive pointed out that an FDA enforcement stance does not shield brands from consumer lawsuits. Zero-sugar claims on products made with allulose have drawn a wave of suits despite similar FDA guidance.
Sources: FDA letter to Gourmend Foods (Nov. 16, 2026); Food Dive (Sarah Zimmerman, Nov. 19, 2026); Institute for Justice (Nov. 17, 2026); Institute for Justice on the Ninth Circuit ruling (Aug. 4, 2026).
